Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy.
Saved in:
| Title: | Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy. |
|---|---|
| Authors: | Kuang AG; Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania Health System, Philadelphia, PA, USA., Shatila M; Division of Internal Medicine, Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shah JS; Department of Medicine, Baylor College of Medicine, Houston, TX, USA., Mittal N; Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA., Naz S; Division of Internal Medicine, Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ebinama U; Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA., Iyer SP; Division of Cancer Medicine, Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Strati P; Division of Cancer Medicine, Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shafi MA; Division of Internal Medicine, Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thomas AS; Division of Internal Medicine, Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang HC; Division of Internal Medicine, Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang Y; Division of Internal Medicine, Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1466, Houston, TX 77030, USA. |
| Source: | Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2026 Feb 15; Vol. 18, pp. 17588359261417635. Date of Electronic Publication: 2026 Feb 15 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
